Loading
Metastatic/locally Advanced Poorly Differentiated NEC / Tarlatamab / Metastatic/locally Advanced Small Cell Lung Cancer · Phase 2 Trial
ClinicalTrials.gov · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned Phase 2 platform study evaluating tarlatamab, a DLL3-targeting therapy, in metastatic/locally advanced SCLC (any DLL3 level) and poorly differentiated NECs (DLL3-positive). No efficacy or safety results are posted in this registry record; the study is actively recruiting and primary outcomes have not yet been assessed.
Phase 2, Interventional, Non Randomized, Parallel, Open label, Treatment purpose. Metastatic/Locally Advanced Small-Cell Lung Cancer, Metastatic/Locally Advanced Poorly Differentiated NEC; age from 18 Years. Intervention: Cohort 1; Cohort 2. n = 40. 3 sites: France.
This is a planned Phase 2 platform study evaluating tarlatamab, a DLL3-targeting therapy, in metastatic/locally advanced SCLC (any DLL3 level) and poorly differentiated NECs (DLL3-positive). No efficacy or safety results are posted in this registry record; the study is actively recruiting and primary outcomes have not yet been assessed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This registry record documents a planned study but provides no evidence on tarlatamab efficacy or safety. Clinicians should await published Phase 2 results before considering this agent, and note the biomarker-driven approach (DLL3 expression).
This is a clinical trial registry record describing a planned Phase 2 study with no results reported; it documents study design and biomarker strategy but carries no efficacy or safety data.
As stated by the source record.
Quoted from the source exactly as published.
This registry record documents a planned study but provides no evidence on tarlatamab efficacy or safety. Clinicians should await published Phase 2 results before considering this agent, and note the biomarker-driven approach (DLL3 expression).
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07016230). This is a study registration, not published results. Lead sponsor: Gustave Roussy, Cancer Campus, Grand Paris. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 40 participants (ESTIMATED). Conditions: Metastatic/Locally Advanced Small-Cell Lung Cancer, Metastatic/Locally Advanced Poorly Differentiated NEC. Interventions: DRUG: Tarlatamab. Primary outcome measures: To estimate the objective response rate (ORR) , Within the 4 months of treatment initiation. Brief summary: UNLOCK TARLATAMAB is an open-label, single arm, multicenter, phase 2 platform study that aims to evaluate the mechanisms of action and resistance to tarlatamab in metastatic/locally advanced Small-Cell Lung Cancer (SCLC) with any level of DLL3 expression and in other poorly differentiated Neuroendocrine Carcinomas (NECs) DLL3 positive. The two cohorts of patients are the following: i. cohort 1: patients with SCLC with any level of DLL3 expression. ii. cohort 2: patients with other poorly differentiated NECs whatever the primary or high grade medullary thyroid carcinoma DLL3 positive by immunohistochemistry (IHC). Patients enrolled in both cohorts will receive treatment with tarlatamab at the dose of 1 mg on D1, 10 mg on D8 and D15 and Q2W thereafter in a 28-day cycle. Tarlatamab will be administrated in intravenous route until disease progression, unacceptable toxicity, or consent withdrawal. Tumor and blood samples will be collected at baseline, on-treatment and at progression in order to identify biomarkers of drug response
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.